PMC6554518_01
iStent  Trabecular Micro-Bypass.
OPTH-13-869-g0003.jpg
PMC6554518_01_OPTH-13-869-g0003.jpg
F0001
 In the Controlled Group aiming for medication reduction, mean medication number was reduced by 77.3% (from 2.6+-0.8 medications preoperatively to 0.6+-0.8 medications at 36 months; p<0.001) (Figure 3). Meanwhile, IOP also decreased significantly (13.5+-1.8 mmHg preoperatively vs 12.6+-2.6 mmHg at 36 months; p=0.028) (Figure 3). 
iStent  implantation location.
OPTH-13-869-g0004.jpg
PMC6554518_01_OPTH-13-869-g0004.jpg
F0002
All Controlled eyes maintained or reduced their medication burden versus preoperative; no eyes were on >=3 medications (vs 61.2% preoperatively), and 58.3% of eyes were medication-free (versus 0% preoperatively) (Table 3, Figure 4). Additionally, 94.4% of eyes maintained or reduced their medication burden versus preoperative, including a greater than 90% decrease (57.9% to 5.6%) in the proportion of eyes with high medication burden (>=3 medications) (Figure 6, Table 4). 
Mean medication burden and IOP through 36 months postoperative, Controlled Group (goal to reduce medications), Consistent Cohort (n=49).
OPTH-13-869-g0005.jpg
PMC6554518_01_OPTH-13-869-g0005.jpg
F0003
 In the Uncontrolled Group desiring IOP reduction, mean IOP decreased by 31.2% (19.4+-3.7 mmHg preoperatively vs 13.4+-2.0 mmHg at 36 months; p<0.001) (Figure 5). Although medication reduction was not expected to accompany IOP reduction, a 45.3% medication reduction did occur (2.2+-1.2 medications preoperatively vs 1.2+-1.0 at 36 months; p<0.001) (Figure 5).
Proportional analysis of medication burden through 36 months postoperative, Controlled Group, Consistent Cohort (n=49).
OPTH-13-869-g0006.jpg
PMC6554518_01_OPTH-13-869-g0006.jpg
F0004
Additionally, 94.4% of eyes maintained or reduced their medication burden versus preoperative, including a greater than 90% decrease (57.9% to 5.6%) in the proportion of eyes with high medication burden (>=3 medications) (Figure 6, Table 4). 